A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.-Reference-Cited by-同舟云学术

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:102-102
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Drilon Alexander E.¹,Subbiah Vivek²,Oxnard Geoffrey R.³,Bauer Todd Michael⁴,Velcheti Vamsidhar⁵,Lakhani Nehal J.⁶,Besse Benjamin⁷,Park Keunchil⁸,Patel Jyoti D.⁹,Cabanillas Maria E.²,Johnson Melissa Lynne¹⁰,Reckamp Karen L.¹¹,Boni Valentina¹²,Loong Herbert H. F.¹³,Schlumberger Martin¹⁴,Solomon Ben¹⁵,Cruickshank Scott¹⁶,Rothenberg Stephen M.¹⁷,Shah Manisha H.¹⁸,Wirth Lori J.¹⁹

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY;

2. The University of Texas MD Anderson Cancer Center, Houston, TX;

3. Dana-Farber Cancer Institute, Boston, MA;

4. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;

5. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;

6. START Midwest, Grand Rapids, MI;

7. Gustave Roussy, Villejuif, France;

8. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;

9. University of Chicago, Chicago, IL;

10. Sarah Cannon Research Institute, Nashville, TN;

11. City of Hope Comprehensive Cancer Center, Duarte, CA;